On June 25th, the National Medical Products Administration (NMPA) approved the marketing application of Novo Nordisk's Novo Nordisk developed and produced Novo Nordisk's Novo Nordisk Injection (for long-term weight management) in China. Regarding whether the drug will participate in this year's national medical insurance negotiations, Novo Nordisk responded by stating that it will immediately initiate various work such as online listing and hospital medication administration in various regions after Novo Nordisk's approval, in order to help obese patients use this innovative drug for treatment as soon as possible.